Recent Finacing
Recent Raise
Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies (BOW015, BOW050, BOW030), conducts Phase 1–3 clinical programs, and commercializes via local partnerships, in‑market SCALE manufacturing, and distributor/direct sales.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors